TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7755658

Group type: EXPERIMENTAL
Intervention: Heterozygous familial hypercholesterolaemia (FH)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Normocholesterolaemic subjects (Control)
Number of subjects: 12
Study: 2148629

Group type: EXPERIMENTAL
Intervention: Tigason alone
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Tigason combined with PUVA
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Tigason combined with SUP
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Roaccutan
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Retinoids (Tigason and Roaccutan)
Number of subjects: 88
Study: 344914

Group type: EXPERIMENTAL
Intervention: Cephaloridine prophylaxis
Number of subjects: 139

Group type: COMPARATOR
Intervention: Placebo prophylaxis
Number of subjects: 139
Study: 31162140

Group type: EXPERIMENTAL
Intervention: NT-proBNP concentration (doubling) among white individuals
Number of subjects: 3610

Group type: EXPERIMENTAL
Intervention: NT-proBNP concentration (doubling) among black individuals
Number of subjects: 3610

Group type: EXPERIMENTAL
Intervention: NT-proBNP predictive ability across BMI and eGFR categories among white individuals
Number of subjects: 3610

Group type: EXPERIMENTAL
Intervention: NT-proBNP predictive ability among black individuals with obesity (BMI ≥ 30 kg/m2) or eGFR < 60 mL/min/1.73 m2
Number of subjects: 3610
Study: 28738079

Group type: EXPERIMENTAL
Intervention: Ozone (20 μg/ml)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 25606478

Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nitroglycerin
Number of subjects: 60
Study: 23835693

Group type: EXPERIMENTAL
Intervention: Intensive treatment group (DCCT)
Number of subjects: 1441

Group type: COMPARATOR
Intervention: Conventional treatment group (DCCT)
Number of subjects: 1441
Study: 21245182

Group type: EXPERIMENTAL
Intervention: Escitalopram (10-20 mg/d)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205
Study: 19966532

Group type: EXPERIMENTAL
Intervention: Daikenchuto
Number of subjects: 14

Group type: COMPARATOR
Intervention: Orengedokuto
Number of subjects: 14

Group type: COMPARATOR
Intervention: Water
Number of subjects: 14
Study: 17124698

Group type: EXPERIMENTAL
Intervention: Joint modelling of repeated measurements and competing risks failure time data
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Joint modelling approach
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EM-based algorithm for parameter estimates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simulation study
Number of subjects: 0
Study: 15296554

Group type: EXPERIMENTAL
Intervention: Gallstones diagnosed by ultrasound scan
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Patients operated on for gallstone disease
Number of subjects: 75

Group type: COMPARATOR
Intervention: Patients not operated on for gallstones
Number of subjects: 75

Group type: COMPARATOR
Intervention: Patients without gallstones
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 75
Study: 11339520

Group type: EXPERIMENTAL
Intervention: Oral suspension of meloxicam 7.5 mg daily
Number of subjects: 286

Group type: COMPARATOR
Intervention: Solid formulation of meloxicam 15 mg
Number of subjects: 286
Study: 9213408

Group type: EXPERIMENTAL
Intervention: Icelandic Moss (Cetraria islandica) lozenges, 0.48 g per day (10 lozenges per day)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 61
Study: 7864949

Group type: EXPERIMENTAL
Intervention: Albuterol delivered by metered-dose inhaler (MDI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo inhaler
Number of subjects: 0
Study: 3666666

Group type: EXPERIMENTAL
Intervention: pirenzepine 50 mg b.i.d.
Number of subjects: 30

Group type: COMPARATOR
Intervention: ranitidine 150 mg b.i.d.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: pirenzepine
Number of subjects: 30
Study: 30224261

Group type: EXPERIMENTAL
Intervention: CHA2DS2‐VASc based anticoagulant treatment recommendation
Number of subjects: 2355

Group type: COMPARATOR
Intervention: Care as usual (reference practices)
Number of subjects: 2355
Study: 28246005

Group type: EXPERIMENTAL
Intervention: Ventricular-arterial coupling (Ea/Ees ratio)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Load-independent contractility (Ees, PRSW)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: LV global longitudinal strain (GLS)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Mitral E-wave over annular velocity E' ratio (E/E')
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Left ventricular ejection fraction (EF)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Classification and regression analysis
Number of subjects: 234
Study: 26374635

Group type: EXPERIMENTAL
Intervention: Eccentric-focused training group (ETG)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Conventional training group (CTG)
Number of subjects: 26
Study: 24284242

Group type: EXPERIMENTAL
Intervention: BMMCs with porous hydroxylapatite composite
Number of subjects: 35

Group type: COMPARATOR
Intervention: Cell-free porous hydroxylapatite composite
Number of subjects: 35
Study: 20553856

Group type: EXPERIMENTAL
Intervention: Repeated antenatal corticosteroid treatment
Number of subjects: 51

Group type: COMPARATOR
Intervention: Single antenatal corticosteroid treatment
Number of subjects: 51
Study: 19007589

Group type: EXPERIMENTAL
Intervention: Tolvaptan 15 mg
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Tolvaptan 30 mg
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Tolvaptan 60 mg
Number of subjects: 181

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study: 15728062

Group type: EXPERIMENTAL
Intervention: Impervious surgical drape
Number of subjects: 8

Group type: COMPARATOR
Intervention: Large Surgical Drape
Number of subjects: 8

Group type: COMPARATOR
Intervention: Medline Proxima
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Moist skin
Number of subjects: 8
Study: 12929196

Group type: EXPERIMENTAL
Intervention: Intramuscular caffeine injection (0.5 ml, 20 mM)
Number of subjects: 17
Study: 10812530

Group type: EXPERIMENTAL
Intervention: Pramipexole 1.0 mg per day
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Pramipexole 5.0 mg per day
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg
Number of subjects: 174

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study: 8692301

Group type: EXPERIMENTAL
Intervention: Endoscopic CO2 laser vaporization treatment
Number of subjects: 46
Study: 1519524

Group type: EXPERIMENTAL
Intervention: Angina-directed medical therapy
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Angina plus ambulatory electrocardiographic-directed medical therapy
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Revascularization
Number of subjects: 600

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study: 6234281

Group type: EXPERIMENTAL
Intervention: 400 mg bd norfloxacin
Number of subjects: 122

Group type: COMPARATOR
Intervention: 160/800 mg bd cotrimoxazole
Number of subjects: 122
Study: 30777705

Group type: EXPERIMENTAL
Intervention: Exercise videogames
Number of subjects: 283

Group type: COMPARATOR
Intervention: Standard exercise
Number of subjects: 283

Group type: COMPARATOR
Intervention: Control
Number of subjects: 283
Study: 29633025

Group type: EXPERIMENTAL
Intervention: 200-μg vaginal misoprostol, 3 hours prior to vaginoscopic hysteroscopy
Number of subjects: 122

Group type: COMPARATOR
Intervention: No drug (control group)
Number of subjects: 122
Study: 26541687

Group type: EXPERIMENTAL
Intervention: Antidepressants (sertraline and mianserin)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Flexible cognitive-behavioural therapy (CBT)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Psychotherapy
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Combination of psychotherapy and medicine
Number of subjects: 280
Study: 24637803

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (OT)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 22119063

Group type: EXPERIMENTAL
Intervention: Olmesartan (20-40mg)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Control
Number of subjects: 247
Study: 19286598

Group type: EXPERIMENTAL
Intervention: Treatment arms from various clinical trials for acute stroke
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: National Institute of Neurological Diseases and Stroke intravenous recombinant tissue plasminogen activator trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stroke‐Acute Ischemic NXY Treatment and Abciximab Emergent Stroke Treatment Trial
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pooled control arms from randomized controlled trials
Number of subjects: 0
Study: 17468087

Group type: EXPERIMENTAL
Intervention: Zinc + Iron + Vitamin A (Zn+Fe+vit.A)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Zinc + Iron (Zn+Fe)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Zinc alone (Zn)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 800
Study: 16181237

Group type: EXPERIMENTAL
Intervention: Lipid infusion
Number of subjects: 6

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 6
Study: 11879254

Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg (intravenous)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Sildenafil 100 mg (oral) in fed state
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg (oral) in fasted state
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Sildenafil doses of 25, 50, 100, and 200 mg (oral)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Sildenafil (various doses)
Number of subjects: 78
Study: 10073874

Group type: EXPERIMENTAL
Intervention: Telepress program for self-measurement of blood pressure
Number of subjects: 30
Study: 7721431

Group type: EXPERIMENTAL
Intervention: Intralipid/heparin
Number of subjects: 19

Group type: COMPARATOR
Intervention: saline/heparin
Number of subjects: 19

Group type: COMPARATOR
Intervention: dextrose/heparin
Number of subjects: 19
Study: 1645503

Group type: EXPERIMENTAL
Intervention: Single-dose oral therapy with azithromycin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard 7-day twice-daily course of doxycycline
Number of subjects: 0
Study: 6939008

Group type: EXPERIMENTAL
Intervention: Lithium treatment
Number of subjects: 6
Study: 31034640

Group type: EXPERIMENTAL
Intervention: 300 min/wk aerobic exercise (HIGH dose group)
Number of subjects: 400

Group type: COMPARATOR
Intervention: 150 min/wk aerobic exercise (MODERATE dose group)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Impact exercises (exploratory analysis)
Number of subjects: 400
Study: 29514699

Group type: EXPERIMENTAL
Intervention: Risk-reframing (RR) digital tool and in-person workshop
Number of subjects: 501

Group type: COMPARATOR
Intervention: Position Statement on Active Outdoor Play (Control)
Number of subjects: 501
Study: 26930244

Group type: EXPERIMENTAL
Intervention: Medulla powder (15 g/day)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Whole fruit powder (15 g/day)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 24835379

Group type: EXPERIMENTAL
Intervention: Oesophageal flap valvuloplasty and wrapping suturing technique
Number of subjects: 394

Group type: COMPARATOR
Intervention: Traditional techniques (Control)
Number of subjects: 394
Study: 22702540

Group type: EXPERIMENTAL
Intervention: Erythropoiesis stimulating agents (ESAs)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Poor response to ESAs
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Age and co-morbidities
Number of subjects: 302
Study: 19915503

Group type: EXPERIMENTAL
Intervention: CHO + PRO
Number of subjects: 8

Group type: COMPARATOR
Intervention: CHO
Number of subjects: 8
Study: 17634728

Group type: EXPERIMENTAL
Intervention: Dentifrice containing 550 microg F/g, pH 5.5 (experimental)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Dentifrice containing 1, 100 microg F/g, pH 7.0 (positive control)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Non-fluoridated dentifrice (negative control)
Number of subjects: 6
Study: 15070956

Group type: EXPERIMENTAL
Intervention: Low sodium diet (1.3 g, 57 mmol)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: High sodium diet (4 g, 172 mmol)
Number of subjects: 36
Study: 11778680

Group type: EXPERIMENTAL
Intervention: Randomization bootstrap
Number of subjects: 0

Group type: COMPARATOR
Intervention: Established approach (randomization or permutation tests)
Number of subjects: 0
Study: 9893098

Group type: EXPERIMENTAL
Intervention: Cafestol (1, 2, or 3 cups of French-press coffee)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Kahweol (1, 2, or 3 cups of French-press coffee)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Cafestol
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Kahweol
Number of subjects: 9
Study: 8064943

Group type: EXPERIMENTAL
Intervention: Chloroquine phosphate (5 mg base kg‐1)
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Placebo (multivitamin tablet)
Number of subjects: 2000
Study: 3056948

Group type: EXPERIMENTAL
Intervention: Transcutaneous reduction and external fixation
Number of subjects: 31

Group type: COMPARATOR
Intervention: Closed manipulation
Number of subjects: 31
Study: 1200338

Group type: EXPERIMENTAL
Intervention: Intramuscular chlorprothixene (1 mg/kg)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Oral chlorprothixene (4% solution, 1.5-2 mg/kg)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Intramuscular 1-hyoscyamine (0.005-0.01 mg/kg)
Number of subjects: 200
Study: 31831845

Group type: EXPERIMENTAL
Intervention: Haploidentical donor (HID) transplantation
Number of subjects: 189

Group type: COMPARATOR
Intervention: HLA-matched sibling donor (MSD) transplantation
Number of subjects: 189
Study: 30905725

Group type: EXPERIMENTAL
Intervention: 1 D more hyperopic refractive error
Number of subjects: 33526

Group type: COMPARATOR
Intervention: Mendelian randomization analysis
Number of subjects: 33526
Study: 28637654

Group type: EXPERIMENTAL
Intervention: Instrument-based vision screening
Number of subjects: 12
Study: 26001837

Group type: EXPERIMENTAL
Intervention: Cardiac output-guided haemodynamic therapy
Number of subjects: 723

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 723
Study: 21983702

Group type: EXPERIMENTAL
Intervention: Spacer plate with 6 weeks of feather-touch weight bearing
Number of subjects: 30

Group type: COMPARATOR
Intervention: Plate fixator with 2 weeks of feather-touch weight bearing
Number of subjects: 30
Study: 20882294

Group type: EXPERIMENTAL
Intervention: Moderate fatigue sensation (Borg's CR‐10 3) during static contractions
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Strong fatigue sensation (Borg's CR‐10 5) during static contractions
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 10% maximum pulling force (MVC) during static contractions
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 40% maximum pulling force (MVC) during static contractions
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Rest condition with stretch exercise
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Rest condition without stretch exercise
Number of subjects: 11
Study: 18303227

Group type: EXPERIMENTAL
Intervention: Deep sclerectomy with low-dosage mitomycin C (DSMMC)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Trabeculectomy with low-dosage mitomycin C (TPMMC)
Number of subjects: 40
Study: 16938002

Group type: EXPERIMENTAL
Intervention: 8-session educational intervention
Number of subjects: 165
Study: 12563691

Group type: EXPERIMENTAL
Intervention: Training of x-ray technologists in fluoroscopically assisted semiflexed knee examination and quality control criteria (QCC) for film acceptance.
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: NA technologists' JSW measurement
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: EU technologists' JSW measurement
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Overall technologists' reproducibility
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Reproducibility in joint repositioning
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Between-continent precision of JSW measurements
Number of subjects: 199
Study: 10661690

Group type: EXPERIMENTAL
Intervention: Alcohol (75 ml)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Alcohol
Number of subjects: 12
Study: 9403805

Group type: EXPERIMENTAL
Intervention: TRH injection (0.2 mg protirelin, iv)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Atropine (1 mg, iv)
Number of subjects: 10
Study: 8170764

Group type: EXPERIMENTAL
Intervention: Paced walking at controlled moderate intensity for 30 min at 11:50 a.m.
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Paced walking at controlled moderate intensity for 40 min at 11:50 a.m.
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Paced walking at controlled moderate intensity for 30 min at 2:20 p.m.
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Paced walking at controlled moderate intensity for 40 min at 2:20 p.m.
Number of subjects: 120

Group type: COMPARATOR
Intervention: Paced walking at controlled moderate intensity for 20 min at any time of the day.
Number of subjects: 120
Study: 3535446

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 30009636

Group type: EXPERIMENTAL
Intervention: Virtual reality training promoting exercise
Number of subjects: 64

Group type: COMPARATOR
Intervention: Routine care (advice on physical activities)
Number of subjects: 64
Study: 30186631

Group type: EXPERIMENTAL
Intervention: Prolonged hemodialysis (PHD) sessions lasting 10 hours
Number of subjects: 194

Group type: COMPARATOR
Intervention: Prolonged hemodialysis (PHD) sessions lasting 6 hours
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Prolonged hemodialysis (PHD) sessions (both 6h and 10h)
Number of subjects: 194
Study: 27768517

Group type: EXPERIMENTAL
Intervention: No fluid intake (NF)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Water intake (WATER)
Number of subjects: 8
Study: 26242177

Group type: EXPERIMENTAL
Intervention: Continuous infusion of rocuronium 0.6 mg/kg per hour
Number of subjects: 66

Group type: COMPARATOR
Intervention: Continuous infusion of NaCl 0.9 % 0.06 ml/kg per hour
Number of subjects: 66
Study: 23954097

Group type: EXPERIMENTAL
Intervention: Calcium carbonate (1,000 mg as elemental calcium) with vitamin D‐3 (400 IU) daily
Number of subjects: 1911

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1911
Study: 20948291

Group type: EXPERIMENTAL
Intervention: Muromonab CD3 (monoclonal antibody targeting CD3)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel monoclonal antibodies targeting co‐stimulatory signals, cell surface receptors, and novel protein constructs
Number of subjects: 0
Study: 18853593

Group type: EXPERIMENTAL
Intervention: Miller blade with paraglossal approach
Number of subjects: 161

Group type: COMPARATOR
Intervention: Macintosh blade using standard approach
Number of subjects: 161
Study: 16844630

Group type: EXPERIMENTAL
Intervention: Bonanno catheter
Number of subjects: 38

Group type: COMPARATOR
Intervention: Tube thoracostomy
Number of subjects: 38
Study: 12727577

Group type: EXPERIMENTAL
Intervention: Aggressive lipid-lowering strategy involving up to 80 mg/d of atorvastatin with a target LDL cholesterol level <77 mg/dL
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Aggressive lipid-lowering strategy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual therapy of lipids with LDL cholesterol target level <116 mg/dL
Number of subjects: 60
Study: 11253439

Group type: EXPERIMENTAL
Intervention: Increased age
Number of subjects: 2324

Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 2324

Group type: EXPERIMENTAL
Intervention: Greater sun sensitivity
Number of subjects: 2324
Study: 9404128

Group type: EXPERIMENTAL
Intervention: Propofol anesthesia
Number of subjects: 60

Group type: COMPARATOR
Intervention: Inhalational anesthesia (nitrous oxide-oxygen-isoflurane/sevoflurane)
Number of subjects: 60
Study: 8222384

Group type: EXPERIMENTAL
Intervention: 0.4 mg SIN-1 administered via intracoronary route
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 0.4 mg SIN-1 administered via intravenous route
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 3899346

Group type: EXPERIMENTAL
Intervention: Chlorambucil (CLR) plus Prednisone (PDN)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Cyclophosphamide (COP)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Patients with previous treatment
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Patients with no previous treatment
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Complete Remission (CR) or good Partial Remission (PR)
Number of subjects: 96
Study: 31564118

Group type: EXPERIMENTAL
Intervention: Pasta made with 60% semolina flour and 40% sprouted chickpea flour (SCF40)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Pasta made with 100% semolina flour (SEM100)
Number of subjects: 22
Study: 29444768

Group type: EXPERIMENTAL
Intervention: Just-in-time information and feedback (JITIF) intervention
Number of subjects: 1048
Study: 27821144

Group type: EXPERIMENTAL
Intervention: Harmonic surgery
Number of subjects: 36

Group type: COMPARATOR
Intervention: Traditional surgery
Number of subjects: 36
Study: 24851997

Group type: EXPERIMENTAL
Intervention: Prophylactic platelet transfusion to maintain platelet counts at or above 50 × 10(9)/l
Number of subjects: 660

Group type: COMPARATOR
Intervention: Prophylactic platelet transfusion to maintain platelet counts at or above 25 × 10(9)/l
Number of subjects: 660
Study: 22871584

Group type: EXPERIMENTAL
Intervention: Straw provided for forage and bedding
Number of subjects: 30

Group type: COMPARATOR
Intervention: No straw provided
Number of subjects: 30
Study: 20177844

Group type: EXPERIMENTAL
Intervention: Interactive internet smoking cessation program
Number of subjects: 2153
Study: 18780884

Group type: EXPERIMENTAL
Intervention: Learning-based sensorimotor training (LBSMT) - Group I (1x/week, 1.5 hours/visit)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Learning-based sensorimotor training (LBSMT) - Group II (3x/week, 0.75 hours/visit)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Learning-based sensorimotor training (LBSMT) - Group III (4x/week, 3 hours/visit)
Number of subjects: 45
Study: 11174383

Group type: EXPERIMENTAL
Intervention: Combined interferon alfa‐2a and extracorporeal photochemotherapy
Number of subjects: 14